> About the CALGB > CALGB History
1956 Acute Leukemia Group B
In 1956, the Acute Leukemia Group B was designated by the clinical studies panel of the Cancer Chemotherapy National Service Center. Under the leadership of Emil Frei III, M.D., the Group performed controlled clinical trials in the acute leukemias, attracting pediatricians, hematologists, and internists with an interest in chemotherapy. [View CALGB History Video (QuickTime)]

1963-1976 Expansion of Scope Multimodality Studies
James F. Holland, M.D. was named Group Chair in 1963. Research expanded to include pediatric neoplasms (1963), multimodality treatment of Wilms' tumor (1965), certain adult solid tumors (1968), and breast cancer (1969). During this time, principles of chemotherapy derived from acute leukemia studies were translated into applications for solid tumors. Immunotherapy, pathology, psychiatry, radiotherapy, and surgery modality committees were developed to broaden the scope of clinical investigation. The name was changed to the Cancer and Leukemia Group B in 1976 to reflect the inclusion of solid tumors addressed by Group studies.

1981-1986 CCOP, CGOP and Minority Programs
In 1981, Dr. Frei returned as Group Chair. To reflect the group's reorganization, the CALGB directed its clinical research efforts in the areas of leukemia, lymphoma, and breast and respiratory cancer. In 1983, the CALGB became a research base for Community Clinical Oncology Programs (CCOPs), and in 1985, other community hospitals began to participate in CALGB clinical trials through the CooperativeGroup Outreach Program (CGOP) grant.

1989-1994 Group Leaders and CALGB Advancements
In 1989, O. Ross McIntyre, M.D. was elected Group Chair, and Stephen George, Ph.D., Professor of Biostatistics for the Duke Comprehensive Cancer Center, was appointed Group Statistician. Cytogenetics, sophisticated immunophenotyping, and gene rearrangement studies added new dimensions to CALGB science, and systematic studies in population pharmacokinetics and studies directed at ascertaining long-term outcomes of cancer treatment and psychosocial adaptation were initiated. Furthermore, the CALGB broadened its area of scientific interest to encompass GI tumors and prostate cancer.

1994 New Group Chair and Relocation of CALGB Central Office
Richard L. Schilsky, M.D., was elected Group Chair in 1994, assuming the Chairmanship on April 1, 1995. The CALGB Central Office relocated from Lebanon, New Hampshire, to downtown Chicago, Illinois, near the University of Chicago.

New Goals
The CALGB will direct its energies to aggressively pursuing new moleculary-targeted therapies, multi-disciplinary treatment, pharmacogenomics, and pharmacogenetics. The CALGB will position itself to move beyond traditional cancer treatment studies into the realm of cancer prevention, a logical extension of the Group's focus on early-stage disease. By developing a more sophisticated approach to risk assessment, a better definition of genetic alterations that contribute to the development of cancer, and a wider range of chemopreventive agents, cancer prevention will be a rewarding area for research.

Board of Directors
The Board of Directors of the CALGB is composed of the Principal Investigator or designated representative from each main member institution and CCOP, elected representation from At-Large Members, the Chair of each Modality Committee, and the members of the Executive Committee. The Board elects the Group Chair and the members of the Executive Committee and has fiduciary responsibilities for CALGB affairs.

Executive Committee
The Executive Committee sets the scientific agenda of the Group by approving protocols at the concept stage. In addition, the Executive Committee approves the appointment of the Chairs of the Disease and Modality committees and is responsible for the management of Group affairs.

Group Chair, Executive Officers, and Group Statistician
The Group Chair is responsible for the scientific and administrative direction of the Group. Appointed by the Chair, the Executive Officers are responsible for relations with the pharmaceutical industry, and overseeing the activities of the Disease and Modality committees. The Group Statistician is ultimately responsible for the appropriate monitoring of Group studies and for all CALGB data management, analysis, and reporting.

Disease Committees
The Disease Committees plan, implement, and evaluate the CALGB treatment studies. Interim meetings of individuals named to the Disease Committee "core" provide an opportunity for intense discussions required for the generation of protocol drafts. A senior level statistician, the Group Chair, Vice Chair or Executive Officer, patient advocates, and liaison members of Correlative Sciences, Clinical Research Associates, Pharmacology & Experimental Therapeutics, Oncology Nursing, and, when relevant, other Modality committees are assigned to each core group. This ensures that biostatistical and modality input occurs at the earliest stages of protocol development.

Modality Committees
The Modality Committees provide expert advice to the Disease Committees concerning the application of treatments, serve as a focus of discussion of innovative treatments, critically assess progress in the field relevant to the design and implementation of Group studies, and perform a substantial quality-assurance role. In addition, the Modality Committees may test new ideas in studies that accompany the treatment trials, or, in some cases, may implement initial studies of novel treatment regimens.

Administrative and Ad Hoc Scientific Committees
The Administrative Committees are responsible for well-defined areas of Group administration. Ad Hoc Scientific and Administrative committees are appointed by the Group Chair, as necessary, to carry out additional work required by the Group.

CALGB Administrative Committees
Biospecimen and Correlative Sciences Advisory
Committee on Advocacy, Research Communication, Ethics and Disparities (CARE)
Conflict of Interest
Data and Safety Monitoring Board
Institutional Performance Evaluation Committee
Radiation Oncology Quality Improvement

CALGB Modality Committees
Cancer Control and Health Outcomes
Cancer in the Elderly
Clinical Research Associates
Karotype Review
Leukemia Correlative Sciences
Oncology Nursing
Pharmacology and Experimental Therapeutics
Radiation Oncology

CALGB Diesease Committees

printer friendly
Copyright © CALGB 2004
All rights reserved
Last Modified: November 15, 2012
Contact the webmaster